Bright Path Laboratories is a pharmaceutical company committed to changing the way American medicine is sourced and manufactured. By using a continuous flow platform and their patented Spinning-Tube-in-Tube (STT) Reactor™, Bright Path produces large quantities of medicine more quickly, cost-effectively, and with superior quality compared to competitors.
The continuous flow technology enables materials to seamlessly transition through interconnected reactors, with the output of one step flowing directly into the next. This process allows for the continuous addition of components without interrupting the high-quality production of the final product. The design's versatility, reliability, and scalability facilitate large-scale production in compact spaces and within shorter timeframes.
The STT Reactor™, a compact and scalable technology, efficiently synthesizes materials into usable molecules. Its unique design, with a central cylinder within an outer tube, akin to a pen and its cap, allows for exceptionally efficient mixing. As materials flow through the narrow gap between the cylinder and outer tube, the spinning motion enhances mass and heat transfer, ensuring the highest quality and purity of active pharmaceutical ingredients (APIs).
Artificial intelligence, combined with in-line infrared spectroscopy, provides real-time data that enhances reaction efficiency and allows precise control over the process. The STT Reactor™'s efficiency also helps avoid the use of harmful additives, such as toxic catalysts and hazardous solvents, common in traditional batch methods. Bright Path further ensures sustainability by using the EPA’s GREENSCOPE (Gauging Reaction Effectiveness for the Environmental Sustainability of Chemistries with a multi-Objective Process Evaluator) assessment tool to evaluate and optimize their chemical processes and designs. Bright Path is dedicated to creating a secure and sustainable supply chain, ensuring every patient can access safe and affordable medicine.
